Adverse reactions ≥5% in placebo-controlled trials1,a
These are the most common adverse reactions reported in ≥5% of patients treated with Ozempic® in placebo-controlled trials1
Safety profile for once-weekly Ozempic®
Adverse reactions ≥5% in placebo-controlled trials1,a

These are the most common adverse reactions reported in ≥5% of patients treated with Ozempic® in placebo-controlled trials.1 For placebo (n=262), Ozempic® 0.5 mg (n=260), and Ozempic® 1 mg (n=261), respectively, they were:
Nausea (6.1%, 15.8%, 20.3%)
Vomiting (2.3%, 5.0%, 9.2%)
Diarrhea (1.9%, 8.5%, 8.8%)
Abdominal pain (4.6%, 7.3%, 5.7%)
Constipation (1.5%, 5.0%, 3.1%)
aDoes not include SUSTAIN 9.
Hypoglycemia adverse reactions in placebo-controlled trials1,b
Monotherapy (30 weeks)1
For patients taking placebo (n=129), Ozempic® 0.5 mg (n=127), and Ozempic® 1 mg (n=130), respectively, the hypoglycemia adverse reactions were:
Severec (0%, 0%, 0%)
Documented symptomaticd (0%, 1.6%, 3.8%)
Severec or blood glucose-confirmed symptomatice (1.6%, 0%, 0%)

Add-on to basal insulin with or without metformin1
For patients taking placebo (n=132), Ozempic® 0.5 mg (n=132), and Ozempic® 1 mg (n=131), respectively, the hypoglycemia adverse reactions were:
Severec (0%, 0%, 1.5%)
Documented symptomaticd (15.2%, 16.7%, 29.8%)
Severec or blood glucose-confirmed symptomatice (5.3%, 8.3%, 10.7%)

bAmerican Diabetes Association classified, including hypoglycemia episodes classified as severe, documented symptomatic, asymptomatic, probable symptomatic, and pseudo-hypoglycemia.
cSevere hypoglycemia episodes are defined as requiring the assistance of another person.
d≤70 mg/dL glucose threshold.
e≤56 mg/dL glucose threshold.
- The risk of hypoglycemia is increased when Ozempic® is used in combination with insulin secretagogues (eg, sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of the secretagogue or insulin
